FDA Approval Alert: The Need-to-Know | Adagrasib/Cetuximab in KRAS G12C-Mutated Colorectal Cancer

In June 2024, the FDA granted accelerated approval to adagrasib plus cetuximab for patients with KRAS G12C-mutated colorectal cancer.

Data from the colorectal cancer cohort of the KRYSTAL-1 trial support the accelerated approval of adagrasib/cetuximab in KRAS G12C–mutated disease.
FDA Approves Adagrasib/Cetuximab in KRAS G12C-Mutated CRC
Article
Jun 21, 2024 6:23 PM
Data from the colorectal cancer cohort of the KRYSTAL-1 trial support the accelerated approval of adagrasib/cetuximab in KRAS G12C–mutated disease.